Prof. Andrej Egorov, Ph.D.
Scientific Founder, CSO
Dr. Andrej Egorov received his MD and PhD in St. Petersburg, Russia. The initial topic of his carrier was the research and development of the live cold-adapted attenuated influenza vaccines. From 1996 he has been working as a Professor at the Institute of Applied Microbiology in Vienna, Austria. In 1998 he published his key results http://www.ncbi.nlm.nih.gov/pubmed/9658085 describing influenza NS1 protein truncated mutants defective in interferon antagonizing function. Following research http://www.ncbi.nlm.nih.gov/pubmed/9878611 http://www.ncbi.nlm.nih.gov/pubmed/15542655 http://www.ncbi.nlm.nih.gov/pubmed/16971432 was addressed to the development of a new generation of live influenza vaccine and vectors with manipulated NS1 genes. From 2006 until 2011 Dr. Egorov was the VP Research at Avir Green Hills Biotechnology AG, Austria. In 2016 Dr. Egorov became the founder and CSO of Vacthera BioTech GmbH which develops attenuated influenza vaccine vectors.